Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

Update: 2012-05-23

Description

Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading the androgen receptor protein.

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012.

Comments

In Channel

Effects of vitamin D on prostate cancer: Prof Reinhold Vieth - University of Toronto, Ontario, Canada

2012-05-2406:42

Cancer in the developing world: Dr Tim Rebbeck - University of Pennsylvania, Philadelphia, USA

2012-05-2406:20

Metformin's effect on breast cancer: Dr Vuk Stambolic - Ontario Cancer Institute, Toronto, Canada

2012-05-2403:45

Noninvasive imaging markers in prostate cancer: Dr Michael Evans - Memorial Sloan-Kettering Cancer Center, New York, USA

2012-05-2404:08

EGFR mutation unique to glioblastoma linked to lack of response: Dr Ingo Mellinghoff - Memorial Sloan-Kettering Cancer Center

2012-05-2408:04

Biomarker identified in relation to pazopanib in urothelial cancer: Dr Andrea Necchi - National Cancer Institute of Milan

2012-05-2408:08

Anti-angiogenic agents and cancer stem cells: Dr Max Wicha - University of Michigan, Ann Arbor, USA

2012-05-2408:14

Non invasive biomarkers for prostate cancer

2012-05-2405:35

Hypoxia influenced tumour behaviour in prostate cancer: Dr Michael Milosevic - University of Toronto, Ontario, Canada

2012-05-2406:23

Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

2012-05-2308:19

Selumetinib controlled recurrent low-grade serous ovarian cancer: Dr John Farley - Creighton University, Phoenix, Arizona, USA

2012-05-2306:30

Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

2012-05-2305:25

$Targeted therapy for refractory Ewing’s Sarcoma tumours: Dr Aung Naing -University of Texas MD Anderson Cancer Center$

Targeted therapy for refractory Ewing’s Sarcoma tumours: Dr Aung Naing -University of Texas MD Anderson Cancer Center

2012-05-2304:06

Metformin to slow prostate cancer growth: Dr Anthony Joshua - Princess Margaret Hospital, Toronto, Canada

2012-05-2305:15

Targeting the cancer genome: Dr Bill Sellers - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

2012-05-2309:32

Effects of metformin in pancreatic cancer with diabetes: Prof Donghui Li - University of Texas MD Anderson Cancer Center

2012-05-2303:06

Nutrition and supplements for cancer survivors: Prof Susan Mayne - Yale University, Connecticut, USA

2012-05-0910:08

00:00

Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

#box-pro-ellipsis-176316500892151{-webkit-line-clamp:2;}Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

ecancer.org

Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA